Can I Take Berberine with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Does It Matter for Supplement Interactions?

Resmetirom is the first FDA-approved therapy specifically for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis. The FDA granted approval in March 2024 under the brand name Rezdiffra, making it a landmark treatment for a condition that affects an estimated 1.5 to 6.5 percent of U.S. Adults with significant fibrosis risk [1]. Because MASH patients also frequently use dietary supplements, understanding how those supplements interact with resmetirom is a genuine clinical priority.

How Resmetirom Works

Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist. It mimics the metabolic actions of thyroid hormone in the liver without significantly activating cardiac or bone THR-alpha receptors. By activating hepatic THR-beta, resmetirom increases mitochondrial fatty acid oxidation, reduces liver fat synthesis, and lowers LDL cholesterol and triglycerides [2].

How Resmetirom Is Metabolized

Resmetirom is metabolized primarily by CYP3A4 and, to a lesser extent, by CYP2C8. It is also a substrate of the drug-transporter P-glycoprotein (P-gp). This metabolic profile means any compound that meaningfully inhibits CYP3A4 or P-gp could increase resmetirom systemic exposure and, in theory, amplify both its therapeutic effects and adverse effects. The prescribing information for Rezdiffra explicitly lists moderate and strong CYP3A4 inhibitors as substances requiring caution [3].

The key Phase 3 MAESTRO-NASH trial (N=966) showed that resmetirom 100 mg produced MASH resolution in 25.9% of participants versus 14.2% for placebo at 52 weeks (P<0.001), and fibrosis improvement by at least one stage in 25.9% versus 14.7% (P<0.001) [4]. Those outcomes depend on predictable pharmacokinetics. Anything disrupting resmetirom plasma levels could compromise that profile.

What Is Berberine and Why Is It Relevant to MASH Patients?

Berberine is a plant-derived isoquinoline alkaloid found in goldenseal, barberry, and Oregon grape. It has been studied extensively for blood-glucose lowering, lipid reduction, and, increasingly, for liver fat reduction in metabolic liver disease.

Berberine's Metabolic Mechanisms

Berberine activates AMP-activated protein kinase (AMPK), the same energy-sensing pathway targeted by metformin. In a meta-analysis of 14 randomized trials (N=1,068), berberine 500 mg three times daily reduced fasting blood glucose by a mean of 19.83 mg/dL and triglycerides by 35.7 mg/dL compared with control [5]. Those effects overlap substantially with resmetirom's lipid-lowering and metabolic actions, creating a genuine pharmacodynamic stacking situation.

Berberine in NAFLD and MASH Research

A 2020 randomized controlled trial published in Phytomedicine (N=184) found that berberine 500 mg twice daily for 16 weeks reduced liver fat fraction by ultrasound and lowered ALT in patients with nonalcoholic fatty liver disease (NAFLD) [6]. This is directly relevant: the same patients now being prescribed resmetirom are often the patients who have already tried, or are currently using, berberine for metabolic support.

Why MASH Patients Choose Berberine

Berberine is widely marketed as "nature's metformin." It is available over-the-counter, costs considerably less than prescription insulin sensitizers, and appears in many "liver health" supplement stacks. A significant portion of patients starting Rezdiffra will already be taking berberine, making this interaction question clinically urgent rather than theoretical.

The Pharmacokinetic Interaction: CYP3A4 and P-gp Inhibition

This is the more technically complex of the two interaction pathways, and it carries the greater risk of an unintended clinical consequence.

Berberine as a CYP3A4 Inhibitor

Multiple in vitro and in vivo studies confirm that berberine inhibits CYP3A4 activity. A 2010 pharmacokinetic study in healthy volunteers showed that berberine 300 mg three times daily for 10 days increased cyclosporine (a CYP3A4 substrate) AUC by approximately 35%, confirming clinically meaningful CYP3A4 inhibition at typical supplemental doses [7]. Because resmetirom is a CYP3A4 substrate, berberine's inhibitory effect could raise resmetirom plasma concentrations above the levels studied in MAESTRO-NASH.

Berberine as a P-gp Inhibitor

Berberine also inhibits P-glycoprotein efflux transport. P-gp normally limits gastrointestinal absorption and facilitates biliary and renal elimination of many drugs. Inhibiting P-gp alongside CYP3A4 is a dual-pathway effect that could meaningfully increase resmetirom bioavailability beyond what CYP3A4 inhibition alone would predict.

A 2021 review in the British Journal of Clinical Pharmacology catalogued 65 documented herb-drug interactions involving berberine and highlighted CYP3A4 and P-gp inhibition as the most consistently replicated mechanisms, with clinical significance rated moderate for many commonly used drug substrates [8].

What an Elevated Resmetirom Level Might Mean Clinically

The Rezdiffra prescribing label lists elevated ALT and AST as dose-related adverse events occurring in roughly 4.1% of patients at the 100 mg dose versus 0.8% for placebo in MAESTRO-NASH. An increase in resmetirom plasma exposure from berberine-mediated enzyme inhibition could push liver enzyme elevations higher or increase the rate of adverse events such as nausea (seen in 9.2% on 100 mg vs. 2.9% on placebo) and diarrhea (9.5% vs. 4.6%) [4]. Those are not catastrophic numbers, but they matter for a patient already managing a liver disease.

The Pharmacodynamic Interaction: Additive Metabolic Effects

Beyond enzyme inhibition, berberine and resmetirom target overlapping metabolic pathways. This pharmacodynamic overlap can be either beneficial or problematic depending on context.

Lipid Lowering

Resmetirom reduces LDL cholesterol by a mean of 16.3 mg/dL at 100 mg and triglycerides by approximately 22.7% in MAESTRO-NASH [4]. Berberine independently lowers LDL and triglycerides through AMPK activation and PCSK9 inhibition. Adding berberine to resmetirom therapy may produce additive or near-additive lipid lowering. For most MASH patients, lower LDL is generally beneficial, but triglycerides that drop very sharply could affect the interpretation of follow-up metabolic panels.

Blood Glucose Lowering

Resmetirom's THR-beta activation improves hepatic insulin sensitivity as a secondary effect. Berberine's AMPK-mediated glucose lowering adds to this. For patients not on antidiabetic therapy, the combination is unlikely to cause hypoglycemia (neither drug has a direct insulin-secretagogue mechanism). For patients already taking metformin, SGLT-2 inhibitors, or GLP-1 receptor agonists alongside resmetirom, adding berberine creates a multi-agent glucose-lowering stack where cumulative hypoglycemia risk should be discussed with the prescribing physician.

Liver Enzyme Effects

Both compounds affect liver metabolism at the enzyme level. Berberine has shown ALT-lowering properties in NAFLD trials [6], while resmetirom at therapeutic doses occasionally raises transaminases transiently. The net directional effect of combining them on ALT is not predictable without monitoring. The AASLD 2023 practice guidance on MASH states: "Herbal and dietary supplement use should be reviewed at every clinical visit given the hepatotoxic potential of many agents and the possibility of pharmacokinetic interactions with emerging MASH therapies" [9].

Is There Any Clinical Evidence Specifically on Berberine Plus Resmetirom?

No. As of mid-2025, there are no published randomized controlled trials, pharmacokinetic studies, or prospective cohort analyses examining berberine and resmetirom together. The MAESTRO-NASH trial excluded patients taking supplements with known metabolic activity at the time of screening [4]. This evidence gap is not unusual for a drug approved only in 2024, but it means all guidance in this area derives from first-principles pharmacology rather than direct observation.

HealthRX Clinical Decision Framework: Berberine + Resmetirom

A practical approach for patients already using berberine when resmetirom is prescribed, or who ask about starting berberine during resmetirom therapy:

1. Disclose first. Tell the prescribing physician the dose and formulation of berberine before starting resmetirom, or before adding berberine to an established resmetirom regimen.
2. Baseline labs. Obtain ALT, AST, total bilirubin, fasting glucose, and a full fasting lipid panel before any change in regimen.
3. Conservative berberine dose if approved. If the physician approves concurrent use, consider 500 mg once or twice daily rather than the upper range of 1,500 mg per day, to minimize the magnitude of CYP3A4 inhibition.
4. Repeat labs at 4 weeks. Recheck ALT, AST, and fasting lipids 4 weeks after starting the combination.
5. Watch for GI signal. Nausea and diarrhea are the most common resmetirom adverse effects. An increase in GI symptoms after adding berberine may indicate elevated resmetirom exposure.
6. Hold berberine if ALT exceeds 3x ULN. This threshold is standard in hepatology and aligns with the Rezdiffra prescribing label's guidance on transaminase monitoring.

What the Guidelines Say About Supplements in MASH

AASLD 2023 Position

The American Association for the Study of Liver Diseases 2023 MASH guidance document recommends that clinicians "specifically ask about and document all dietary supplement, herbal product, and over-the-counter medication use" in patients with MASH, noting that "supplement-induced hepatotoxicity accounts for approximately 20% of drug-induced liver injury cases in the United States" [9].

FDA Labeling Guidance on CYP3A4 Inhibitors

The Rezdiffra prescribing information states: "Avoid use of Rezdiffra with strong CYP3A4 inhibitors. Use caution if Rezdiffra is used concomitantly with moderate CYP3A4 inhibitors" [3]. Berberine at doses of 1,000 mg per day and above is generally classified as a moderate CYP3A4 inhibitor in the Natural Medicines database. At 500 mg per day, the inhibitory effect is considered mild to moderate, meaning the FDA's "use caution" language for moderate inhibitors applies at commonly used supplement doses.

Natural Medicines Database Classification

The Natural Medicines professional database rates the berberine-CYP3A4 substrate interaction as "moderate" severity with "fair" evidence quality, recommending clinical monitoring when berberine is used with known CYP3A4 substrates and suggesting the combination be avoided when the substrate has a narrow therapeutic index. Resmetirom does not have a formally established narrow therapeutic index, but given that its efficacy and adverse-event profile are concentration-dependent, the caution is reasonable.

Practical Monitoring Protocol for Patients Using Both

If a physician decides concurrent use is appropriate, the following monitoring schedule is a reasonable minimum.

Before Starting the Combination

• ALT, AST, total bilirubin, alkaline phosphatase
• Fasting blood glucose and HbA1c (if diabetic or prediabetic)
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Review all other medications for CYP3A4 interactions

At 4 Weeks

• Repeat ALT and AST
• Patient symptom review: nausea, diarrhea, right upper quadrant discomfort

At 12 Weeks

• Full liver function panel
• Fasting lipid panel
• Fasting glucose (or HbA1c if diabetic)

Stopping Rules

Discontinue berberine and contact the prescribing physician immediately if:

• ALT or AST rises above 3x the upper limit of normal (ULN)
• New onset of jaundice, dark urine, or right upper quadrant pain
• Unexplained worsening GI symptoms after initiating berberine

Berberine Alternatives That May Carry Less Interaction Risk

Patients using berberine for metabolic support while on resmetirom might consider discussing alternatives with their physician. Omega-3 fatty acids (specifically icosapentaenoic acid at 4 g/day as prescription Vascepa) have a different metabolic mechanism and do not inhibit CYP3A4. A 2019 NEJM paper, REDUCE-IT (N=8,179), showed that icosapentaenoic acid 4 g/day reduced major cardiovascular events by 25% versus placebo [10], suggesting cardiovascular and lipid benefits without the pharmacokinetic conflict. Coenzyme Q10 and vitamin E have also been studied in NAFLD contexts with less interaction concern, though their efficacy data are weaker.

The decision to switch supplements should be made with a physician, not unilaterally.

Special Populations

Patients with Diabetes

Patients with type 2 diabetes represent the majority of MASH patients. Adding berberine on top of resmetirom plus existing antidiabetic regimens requires careful glucose monitoring, specifically fasting glucose and HbA1c at baseline and at 12 weeks. The MAESTRO-NASH trial enrolled a population where approximately 56% had type 2 diabetes [4], so this is not a small subgroup.

Patients with Cirrhosis

Resmetirom is currently indicated for fibrosis stages F2 and F3. Patients with compensated cirrhosis (F4) were not included in MAESTRO-NASH. Both berberine and resmetirom are metabolized hepatically, so impaired liver function could raise exposure to both compounds unpredictably. Berberine use in compensated cirrhosis is not well-studied and should be approached with extra caution.

Patients on Statins

Many MASH patients take statins. Berberine inhibits CYP3A4 and could raise plasma levels of CYP3A4-metabolized statins (simvastatin, lovastatin, atorvastatin). This creates a three-way interaction concern: berberine affecting statin levels while also potentially affecting resmetirom levels. Patients on this triple combination should have creatine kinase monitored in addition to liver function tests.